Related Experiment Video

Updated: Aug 13, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

[Modern diagnosis and treatment methods in hereditary hemochromatosis]

A S Loginov, Iu N Tokarev, D A Settarova

    Terapevticheskii Arkhiv
    |January 1, 1988
    PubMed

    Insights

    Hereditary hemochromatosis diagnosis in 76 patients was confirmed by organ changes. Key lab tests for iron metabolism include transferrin saturation and ferritin levels, with HLA typing for genetic confirmation.

    Area of Science:

    • Internal Medicine
    • Genetics
    • Gastroenterology

    Context:

    • Hereditary hemochromatosis is a genetic disorder characterized by excessive iron absorption.
    • Diagnosis often involves assessing organ damage and laboratory markers.
    • Understanding the genetic basis is crucial for accurate diagnosis and family screening.

    Purpose:

    • To identify the most informative laboratory indices for diagnosing hereditary hemochromatosis.
    • To evaluate the utility of morphological signs in diagnosing the condition.
    • To recommend genetic testing for confirming the hereditary nature of the disease.

    Summary:

    • This study followed 76 hereditary hemochromatosis patients, confirming diagnoses via organ damage (liver, pancreas, lungs, stomach, heart).
    • Identified key laboratory indicators of iron metabolism: transferrin saturation and serum/erythrocyte ferritin levels.
    • Recommended Human Leukocyte Antigen (HLA) typing for probands and relatives to confirm the genetic basis.

    Impact:

    • Provides clear diagnostic criteria for hereditary hemochromatosis.
    • Highlights the importance of specific iron metabolism markers in clinical practice.
    • Emphasizes the role of genetic testing in managing hereditary hemochromatosis and family screening.

    More Related Videos

    Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay05:08

    Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

    Published on: January 31, 2022

    Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron05:36

    Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

    Published on: February 23, 2024

    Related Concept Videos

    Esophageal Varices-II: Clinical Features and Management01:28

    Esophageal Varices-II: Clinical Features and Management

    Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
    In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
    Chronic Pancreatitis II: Collaborative Care01:29

    Chronic Pancreatitis II: Collaborative Care

    The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
    Assessment:
    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...